Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Investor's Business Daily on MSN
Travere, IBD stock of the day, is on path to $3 billion and in a buy zone
Travere Therapeutics is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone after gapping up on an FDA ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 ...
Travere Therapeutics reported its first-quarter 2026 financial results, revealing a mixed performance with earnings per share (EPS) of -$0.40, missing the forecast of -$0.23. The revenue also fell ...
Travere Therapeutics recently reported quarterly results showing higher revenue and a smaller net loss than the prior year, alongside mostly positive Wall Street analyst commentary. At the same time, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results